Cue Biopharma
Cue Biopharma
CUE
NASDAQ
0.72
USD
-29.41%
About
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC).
CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 255.3K |
| Three Month Average Volume | 9.6M |
| High Low | |
| Fifty-Two Week High | 3.2491 USD |
| Fifty-Two Week Low | 0.583 USD |
| Fifty-Two Week High Date | 08 Dec 2023 |
| Fifty-Two Week Low Date | 15 Aug 2024 |
| Price and Volume | |
| Current Price | 0.7225 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -6.32% |
| Thirteen Week Relative Price Change | -58.59% |
| Twenty-Six Week Relative Price Change | -68.86% |
| Fifty-Two Week Relative Price Change | -78.72% |
| Year-to-Date Relative Price Change | -76.89% |
| Price Change | |
| One Day Price Change | 0.21% |
| Thirteen Week Price Change | -55.67% |
| Twenty-Six Week Price Change | -65.76% |
| Five Day Price Change | -6.11% |
| Fifty-Two Week Price Change | -73.34% |
| Year-to-Date Price Change | -72.63% |
| Month-to-Date Price Change | -13.47% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.78545 USD |
| Book Value Per Share (Most Recent Quarter) | 0.4445 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.78545 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.4445 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.98757 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.11999 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.17176 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.1088 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.97434 USD |
| Normalized (Last Fiscal Year) | -1.10541 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.1088 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.97434 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.1088 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.97434 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.02751 USD |
| Cash Per Share (Most Recent Quarter) | 0.61733 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.0949 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.96298 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.7991 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -656 |
| Cash Flow Revenue (Trailing Twelve Months) | -465 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -566.02% |
| Pretax Margin (Last Fiscal Year) | -924.10% |
| Pretax Margin (5 Year) | -806.93% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -949.89% |
| Operating Margin (Trailing Twelve Months) | -582.23% |
| Operating Margin (5 Year) | -816.20% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -924.10% |
| Net Profit Margin (Trailing Twelve Months) | -566.02% |
| Net Profit Margin (5 Year) | -810.87% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -13.71% |
| Tangible Book Value (5 Year) | 1.77% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 92.33% |
| Revenue Growth (3 Year) | 36.88% |
| Revenue Change (Trailing Twelve Months) | 363.92% |
| Revenue Per Share Growth | 16.15% |
| Revenue Growth (5 Year) | 20.29% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 31.13% |
| EPS Change (Trailing Twelve Months) | 23.28% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -23,780,000 |
| Net Debt (Last Fiscal Year) | -40,349,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 6 |
| Price to Sales (Trailing Twelve Months) | 4 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 11 |
| Long Term Debt to Equity (Most Recent Quarter) | 11 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -39,961,000 |
| Free Cash Flow (Trailing Twelve Months) | -38,596,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 22 |
| Total Debt to Equity (Most Recent Quarter) | 29 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -66.40% |
| Return on Assets (Trailing Twelve Months) | -81.32% |
| Return on Assets (5 Year) | -57.45% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -98.73% |
| Return on Equity (Trailing Twelve Months) | -138.87% |
| Return on Equity (5 Year) | -76.41% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -81.71% |
| Return on Investment (Trailing Twelve Months) | -113.52% |
| Return on Investment (5 Year) | -68.41% |